
Tied to the Past, Unprepared for the Future: Meeting the Alzheimer’s Disease Challenge With HEOR
There has been a lot of fanfare about the first 2 medicines capable of slowing the progress of Alzheimer’s disease, lecanemab and donanemab, but their costs over a typical 1.5- to 2-year course of treatment can easily rival the sticker price for the average new car.Yet, without the ability to slow the disease during its earlier symptomatic stages, how much more would society pay as these patients required an extra 6 to 8 months of round-the-clock care, in many cases preventing family caregivers...